These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 15950196)

  • 1. Inhibition of cyclooxygenase with indomethacin phenethylamide reduces atherosclerosis in apoE-null mice.
    Burleigh ME; Babaev VR; Patel MB; Crews BC; Remmel RP; Morrow JD; Oates JA; Marnett LJ; Fazio S; Linton MF
    Biochem Pharmacol; 2005 Aug; 70(3):334-42. PubMed ID: 15950196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice.
    Burleigh ME; Babaev VR; Yancey PG; Major AS; McCaleb JL; Oates JA; Morrow JD; Fazio S; Linton MF
    J Mol Cell Cardiol; 2005 Sep; 39(3):443-52. PubMed ID: 16040051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis.
    Belton OA; Duffy A; Toomey S; Fitzgerald DJ
    Circulation; 2003 Dec; 108(24):3017-23. PubMed ID: 14638539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice.
    Burleigh ME; Babaev VR; Oates JA; Harris RC; Gautam S; Riendeau D; Marnett LJ; Morrow JD; Fazio S; Linton MF
    Circulation; 2002 Apr; 105(15):1816-23. PubMed ID: 11956125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism.
    Egan KM; Wang M; Fries S; Lucitt MB; Zukas AM; Puré E; Lawson JA; FitzGerald GA
    Circulation; 2005 Jan; 111(3):334-42. PubMed ID: 15655126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice.
    Rott D; Zhu J; Burnett MS; Zhou YF; Zalles-Ganley A; Ogunmakinwa J; Epstein SE
    J Am Coll Cardiol; 2003 May; 41(10):1812-9. PubMed ID: 12767669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of cyclooxygenase-1 to thromboxane formation, platelet-vessel wall interactions and atherosclerosis in the ApoE null mouse.
    McClelland S; Gawaz M; Kennerknecht E; Konrad CS; Sauer S; Schuerzinger K; Massberg S; Fitzgerald DJ; Belton O
    Atherosclerosis; 2009 Jan; 202(1):84-91. PubMed ID: 18514659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice.
    Olesen M; Kwong E; Meztli A; Kontny F; Seljeflot I; Arnesen H; Lyngdorf L; Falk E
    Scand Cardiovasc J; 2002 Dec; 36(6):362-7. PubMed ID: 12626204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of cyclooxygenase-1 and -2 in endothelium-dependent contraction of atherosclerotic mouse abdominal aortas.
    Li S; Liu B; Luo W; Zhang Y; Li H; Huang D; Zhou Y
    Clin Exp Pharmacol Physiol; 2016 Jan; 43(1):67-74. PubMed ID: 26444418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
    Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
    Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limited anti-inflammatory efficacy of cyclo-oxygenase-2 inhibition in carrageenan-airpouch inflammation.
    Wallace JL; Chapman K; McKnight W
    Br J Pharmacol; 1999 Mar; 126(5):1200-4. PubMed ID: 10205009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular basis of the time-dependent inhibition of cyclooxygenases by indomethacin.
    Prusakiewicz JJ; Felts AS; Mackenzie BS; Marnett LJ
    Biochemistry; 2004 Dec; 43(49):15439-45. PubMed ID: 15581355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on the metabolism of the novel, selective cyclooxygenase-2 inhibitor indomethacin phenethylamide in rat, mouse, and human liver microsomes: identification of active metabolites.
    Remmel RP; Crews BC; Kozak KR; Kalgutkar AS; Marnett LJ
    Drug Metab Dispos; 2004 Jan; 32(1):113-22. PubMed ID: 14709628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of cyclooxygenases reduces complement-induced glomerular epithelial cell injury and proteinuria in passive Heymann nephritis.
    Takano T; Cybulsky AV; Cupples WA; Ajikobi DO; Papillon J; Aoudjit L
    J Pharmacol Exp Ther; 2003 Apr; 305(1):240-9. PubMed ID: 12649375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The select cyclooxygenase-2 inhibitor celecoxib reduced the extent of atherosclerosis in apo E-/- mice.
    Jacob S; Laury-Kleintop L; Lanza-Jacoby S
    J Surg Res; 2008 May; 146(1):135-42. PubMed ID: 17950326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo.
    Sawaoka H; Tsuji S; Tsujii M; Gunawan ES; Sasaki Y; Kawano S; Hori M
    Lab Invest; 1999 Dec; 79(12):1469-77. PubMed ID: 10616198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclooxygenase-1 deficiency in bone marrow cells increases early atherosclerosis in apolipoprotein E- and low-density lipoprotein receptor-null mice.
    Babaev VR; Ding L; Reese J; Morrow JD; Breyer MD; Dey SK; Fazio S; Linton MF
    Circulation; 2006 Jan; 113(1):108-17. PubMed ID: 16380543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sildenafil (Viagra®) Prevents Cox-1/ TXA2 Pathway-Mediated Vascular Hypercontractility in ApoE-/- Mice.
    Leal MAS; Dias AT; Porto ML; Brun BF; Gava AL; Meyrelles SS; Gil-Longo J; Campos-Toimil M; Pereira TMC; Vasquez EC
    Cell Physiol Biochem; 2017; 44(5):1796-1809. PubMed ID: 29216624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regression of pre-established atherosclerosis in the apoE-/- mouse by conjugated linoleic acid.
    Toomey S; Roche H; Fitzgerald D; Belton O
    Biochem Soc Trans; 2003 Oct; 31(Pt 5):1075-9. PubMed ID: 14505483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclooxygenase inhibitors repress vascular hyaluronan-synthesis in murine atherosclerosis and neointimal thickening.
    Marzoll A; Nagy N; Wördehoff L; Dai G; Fries S; Lindner V; Grosser T; Fischer JW
    J Cell Mol Med; 2009 Sep; 13(9B):3713-9. PubMed ID: 19320776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.